Promising long-term results for rare liver disease drug in kids
NCT ID NCT03659916
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the long-term safety and effectiveness of a drug called A4250 (odevixibat) in 116 children with progressive familial intrahepatic cholestasis (PFIC), a rare liver disease. The children took the drug for up to 72 weeks. The study measured changes in bile acid levels and itching. Results suggest the drug may help control the disease over time, but it is not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BENIGN RECURRENT INTRAHEPATIC CHOLESTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Akdeniz University
Antalya, Turkey (Türkiye)
-
Astrid Lindgren Children's Hospital, Karolinska University Hospital
Solna, Sweden
-
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo, Italy
-
Baylor College of Medicine - Texas Children's Liver Center
Houston, Texas, 77030, United States
-
Birmingham Women's and Children's NHS Foundation Trust
Birmingham, United Kingdom
-
Children's Hospital Colorado
Denver, Colorado, 80045, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15224, United States
-
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Lambert, Belgium
-
Columbia University Medical Center - Presbyterian Hospital Building
New York, New York, 10032, United States
-
Emory University School of Medicine
Atlanta, Georgia, 30329, United States
-
Gazi University
Ankara, Turkey (Türkiye)
-
Hacettepe University Faculty of Medicine
Ankara, Turkey (Türkiye)
-
Hospital De La Timone
Marseille, France
-
Hospital Necker-Enfants Maladies
Paris, France
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital Universitario La Paz
Madrid, Spain
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Inonu University Medical Faculty
Malatya, Turkey (Türkiye)
-
Institute of Liver Studies - Kings College Hospital
London, United Kingdom
-
Instytut Pomnik - Centrum Zarowia Dziecka
Warsaw, Poland
-
Istanbul University Medical Faculty
Istanbul, Turkey (Türkiye)
-
Johns Hopkins School of Medicine
Baltimore, Maryland, 21287, United States
-
Kinderklinik Tubingen, Universitatsklinikum Tubingen
Tübingen, Germany
-
King Faisal Specialist Hospital & Research Centre
Riyadh, Saudi Arabia
-
Leeds General Infirmary
Leeds, United Kingdom
-
Medizinische Hochschule Hannover
Hanover, Germany
-
Ospedale Regina Margherita
Torino, Italy
-
Riley Hospital for Children - Riley Children's Specialists
Indianapolis, Indiana, 46202, United States
-
Schneider Children's Medical Center Of Israel
Petah Tikva, Israel
-
Shaare-Zedek Mc
Jerusalem, Israel
-
The Hospital for Sick Children
Toronto, Canada
-
The Royal Children's Hospital
Melbourne, Australia
-
Universitair Medisch Centrum (UMC) Utrecht
Utrecht, Netherlands
-
Universite Paris SUD - Hpitaux Universitaires Paris-Sud - Hopital Bicetre
Le Kremlin-Bicêtre, France
-
University Hospital Of Padova
Padova, Italy
-
University Medical Center Groningen
Groningen, Netherlands
-
University and Pediatric Hospital of Lyon
Bron, France
-
Univesitatsklinikum Tubingen Klinik fur Kinder und Jugendmedizin
Tübingen, Germany
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a bile acid blocker ease severe itching in a rare liver disease?
- New drug shows promise for babies with rare liver disorders
- New registry tracks Real-World use of PFIC drug odevixibat
- Baby jaundice may leave lasting marks on teeth, new study investigates
- New national registry aims to unlock secrets of rare childhood liver diseases
- New drug shows promise for rare liver disease itch